FIELD: medicine; gastroenterology.
SUBSTANCE: invention concerns selection of eradication therapy for ulcer patients associated with Helicobacter pylori. Invention implies that patients with exacerbation rates more than two times per year are initially prescribed four-component therapy, and patients with two and less exacerbation annually are initially prescribed with three-component therapy.
EFFECT: method provides registration of established dependence between therapeutic effect and annual exacerbation rate, simplification of eradication therapy regardless severity of clinical semiotics.
1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ANTI-HELICOBACTER THERAPY OF STOMACH AND DUODENUM | 2013 |
|
RU2537140C1 |
| DIAGNOSTIC TECHNIQUE FOR DEGREE OF ACTIVITY OF ANTRAL HELICOBACTER-ASSOCIATED GASTRITIS IN PATIENTS WITH BRONCHIAL ASTHMA | 2009 |
|
RU2394499C1 |
| METHOD FOR TREATING HELICOBACTER-ASSOCIATED CHRONIC DUODENAL ULCER | 2003 |
|
RU2252777C2 |
| METHOD OF STOMACH ULCER TREATMENT | 2006 |
|
RU2329810C1 |
| COMPLEX THERAPY METHOD FOR TREATING DUODENAL PEPTIC ULCER DISEASES ASSOCIATED WITH HELICOBACTER PYLORI | 2006 |
|
RU2318514C2 |
| METHOD OF TREATING CHRONIC EROSIVE GASTRITIS ASSOCIATED WITH Helicobacter pylori | 2014 |
|
RU2564963C1 |
| METHOD OF TREATMENT OF CHRONIC EROSIVE GASTRITIS ASSOCIATED WITH HELICOBACTER PYLORI AND EPSTEIN-BARR VIRUS | 2018 |
|
RU2681919C1 |
| METHOD FOR ASSESSING THE SEVERITY OF GASTRIC ULCER WITH ULCER LOCALIZATION IN THE ANTRUM ASSOCIATED WITH HELICOBACTER PYLORI AND EPSTEIN-BARR VIRUS | 2021 |
|
RU2756418C1 |
| PHARMACEUTICAL COMPOSITION OF PROTON PUMP INHIBITOR AND PREBIOTIC FOR TREATING GASTRIC AND DUODENAL ULCERS | 2009 |
|
RU2410100C2 |
| METHOD OF ASSESSMENT OF THE SEVERITY OF THE COURSE OF CHRONIC EROSIVE GASTRITIS ASSOCIATED WITH HELICOBACTER PYLORI AND EPSTEIN-BARR VIRUS | 2017 |
|
RU2659134C1 |
